ClinicalTrials.Veeva

Menu

Association of Brain Derived Neurotrophic Factor (BDNF) rs6265 Gene Polymorphism With Susceptibility to Epilepsy

S

Sohag University

Status

Unknown

Conditions

Epilepsy

Treatments

Genetic: Genotyping by Real Time PCR

Study type

Observational

Funder types

Other

Identifiers

NCT05096871
Soh-Med-21-10-18

Details and patient eligibility

About

Epilepsy is a common neurological condition that affects people of all ages.Recent studies found that epilepsy is associated with several chromosomal regions, where mutations in these regions cause neurological dysfunction.

BDNF which is the most ample neurotropic factor in the CNS, has survival and growth promoting roles in a variety of neurons. It has been shown to promote excitatory (glutamatergic) synapses while weakening inhibitory (GABAergic) ones.

A nonsynonymous G to A single-nucleotide polymorphism (SNP) exists at position 196 of exon 2 (rs6265), which results in valine (val) to methionine (met) substitution. This polymorphism affects intracellular packaging of pro-BDNF, its axonal transport and in turn, activity-dependent secretion of BDNF at the synapse.

Full description

Epilepsy was defined as the separate occurrence of two or more unprovoked seizures, manifested by involuntary motor, sensory, or autonomic, alone or in combination, and not diagnosed as neonatal or febrile seizures. Despite extensive studies, the molecular causes of the disease are not yet discovered completely. A functional imbalance between excitatory (transmitted by glutamate) and inhibitory signals (transmitted by γ-amino butyric acid or GABA) in neural cells has been regarded as a putative contributing factor in epilepsy.

The brain-derived neurotropic factor (BDNF) encodes a small dimeric protein which is the most ample neurotropic factor in the CNS.It has been shown to promote excitatory (glutamatergic) synapses while weakening inhibitory (GABAergic) ones.Any interference with the BDNF signaling pathway may negatively affect downstream neuronal functions and cause neuronal diseases.

A nonsynonymous G to A single-nucleotide polymorphism (SNP) exists at position 196 of exon 2 (rs6265), which results in valine (val) to methionine (met) substitution at codon 66 (val66met), changing the 5' proregion of the human BDNF protein. This polymorphism affects intracellular packaging of pro-BDNF, its axonal transport and in turn, activity-dependent secretion of BDNF at the synapse

Enrollment

90 estimated patients

Sex

All

Ages

1 to 15 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

• Epileptic patients aged more than 1 year and less than 15 year who recently had seizures over a period of one year

Exclusion criteria

  • Patients > 15 years old or less than 1 year.
  • Patients that have epilepsy as a result of head injuries, brain tumors , exposure to low oxygen during birth or infections such as meningitis or encephalitis .
  • Patients that have no sufficient medical records or unreliable seizure frequency,
  • patients with developmental disorders such as Autism and Neurofibromatosis

Trial design

90 participants in 2 patient groups

Group I
Description:
patients with epilepsy
Treatment:
Genetic: Genotyping by Real Time PCR
Group II
Description:
apparently healthy controls with no chronic illness of matched age and sex
Treatment:
Genetic: Genotyping by Real Time PCR

Trial contacts and locations

0

Loading...

Central trial contact

Salma K Abdelmageed, demonstrator

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems